
1. plos negl trop dis. 2019 mar 21;13(3):e0007223. doi:
10.1371/journal.pntd.0007223. ecollection 2019 mar.

the prevalence antifolate drug resistance profiles plasmodium falciparum
in study participants randomized discontinue continue cotrimoxazole
prophylaxis.

juma dw(1), muiruri p(1)(2), yuhas k(3), john-stewart g(4), ottichilo r(1),
waitumbi j(1), singa b(5), polyak c(6)(7), kamau e(1)(6).

author information: 
(1)department emerging infectious diseases (deid), united states army
medical research directorate-africa (usamrd-a), kenya medical research institute 
(kemri) kisumu, kenya.
(2)department biochemistry, jomo kenyatta university agriculture and
technology, nairobi, kenya.
(3)department global health, university washington, seattle, washington
united states america.
(4)departments global health, medicine, epidemiology, pediatrics,
university washington, seattle, washington, united states america.
(5)centre clinical research, kemri, nairobi, kenya.
(6)u.s. military hiv research program, walter reed army institute research,
silver spring, md, united states america.
(7)henry m. jackson foundation advancement military medicine,
bethesda, md, united states america.

objective: cotrimoxazole prevents opportunistic infections including falciparum
malaria hiv-infected individuals concerns cross-resistance to
other antifolate drugs sulphadoxine-pyrimethamine (sp). study, we
investigated prevalence antifolate-resistance mutations plasmodium
falciparum associated sp resistance hiv-infected individuals 
antiretroviral treatment randomized discontinue (stop-ctx), continue (ctx) 
cotrimoxazole western kenya.
design: samples obtained unblinded, non-inferiority randomized
controlled trial participants recruited rolling basis the
first six months study, followed-up 12 months samples
collected enrollment, quarterly, sick visits.
method: plasmodium dna extracted blood specimens. initial screening to
determine presence plasmodium spp. performed quantitative reverse
transcriptase real-time pcr, followed genotyping presence of
sp-resistance associated mutations sanger sequencing.
results: prevalence mutant haplotypes associated sp-resistant
parasites pfdhfr (51i/59r/108n) pfdhps (437g/540e) genes were
significantly higher (p = 0.0006 p = 0.027, respectively) stop-ctx
compared ctx arm. prevalence quintuple haplotype
(51i/59r/108n/437g/540e) 51.8% stop-ctx vs. 6.3% (p = 0.0007) ctx arm. 
there steady increase mutant haplotypes genes stop-ctx arm
overtime study period, reaching statistical significance (p <
0.0001).
conclusion: frequencies mutations pfdhfr pfdhps genes higher
in stop-ctx arm compared ctx arm, suggesting cotrimoxazole effectively
controls selects sp-resistant parasites.
trial registration: clinicaltrials.gov nct01425073.

doi: 10.1371/journal.pntd.0007223 
pmcid: pmc6445470
pmid: 30897090  [indexed medline]

conflict interest statement: authors declared competing
interests exist.

